

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANGZHOU TIGERMED CONSULTING CO., LTD.**

### **杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

## **RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND PROPOSED APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR**

### **Resignation of Independent Non-executive Director**

The board (the “**Board**”) of directors (the “**Directors**, each a “**Director**”) of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) recently received a written resignation from Dr. Yang Bo (楊波博士) (“**Dr. Yang**”), an independent non-executive Director. Dr. Yang has applied for resignation as an independent non-executive Director of the fifth session of the Board due to personal work reasons. At the same time, Dr. Yang has resigned from her positions as the convenor (chairperson) and member of the nomination committee, member of the audit committee and member of the strategy development committee of the fifth session of the Board. After her resignation becomes effective, Dr. Yang will cease to hold any position with the Company.

Dr. Yang confirmed that there is no disagreement between her and the Board. In addition, there are no matters relating to the resignation of Dr. Yang that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Dr. Yang’s resignation as an independent non-executive Director will not take effect until the Shareholders have approved and elected a new Director to fill the casual vacancy at an extraordinary general meeting to be convened and held by the Company (the “**EGM**”). Until then, Dr. Yang will continue to perform her duties as an independent non-executive Director and on the special committees of the Board in accordance with the relevant laws and regulations and the Company’s articles of association.

The Company and the Board would like to express their sincere gratitude to Dr. Yang for her diligent work during her tenure with the Company and her contribution to the development of the Company.

### **Proposed Appointment of an Independent Non-executive Director**

The Board is pleased to announce that on February 27, 2024, the Company convened the fifth meeting of the fifth session of the Board to consider and approve the nomination of Ms. Liu Yuwen (劉毓文) (“**Ms. Liu**”) for proposed appointment as an independent non-executive Director. She will also act as the convenor (chairperson) and a member of the nomination committee, a member of the audit committee and a member of the strategy development committee of the fifth session of the Board, with a term commencing from the date of the approval by Shareholders at the EGM until the conclusion of the fifth session of the Board (the “**proposed appointment of independent non-executive Director**”).

Ms. Liu's curriculum vitae is set out below:

Ms. Liu Yuwen (劉毓文), aged 49. Ms. Liu has been the legal representative and founding partner of Suzhou Industrial Park Bohe Venture Investment Management Co., Ltd.\* (蘇州工業園區薄荷創業投資管理有限公司) since August 2015, served as the executive deputy general manager, chairperson and general manager and executive director of Suzhou Industrial Park Biotech Development Co., Ltd.\* (蘇州工業園區生物產業發展有限公司) (BioBAY) from December 2005 to July 2015, served as the chief representative of the Shanghai representative office of Perrigo International Inc. (美國百利高國際公司) from May 2003 to November 2005 (now known as Perrigo Trading (Shanghai) Co., Ltd.\* (百利高貿易(上海)有限公司)). Ms. Liu also worked as the new business development manager of Suzhou Capsugel Co., Ltd.\* (蘇州膠囊有限公司) (“**Suzhou Capsugel**”), a Sino-US joint venture, from April 2000 to April 2003, the quality control and assurance manager of Suzhou Capsugel from May 1998 to April 2000, and a quality engineer of Suzhou Capsugel from July 1997 to April 1998.

Ms. Liu became a registered pharmacist in 2000, obtained a senior economist certificate from Jiangsu Provincial Department of Human Resources and Social Security in 2013 and obtained the qualification certificate of fund practitioner issued by the Asset Management Association of China in 2016.

Ms. Liu obtained the bachelor's and master's degree in pharmacy from the China Pharmaceutical University in 1994 and 1997, respectively, and a BI-Fudan master's in business and administration offered in partnership by BI Norwegian Business School and Fudan University.

As of the date of this announcement, Ms. Liu has confirmed that, save as disclosed above: (i) she does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (ii) she has no relationship with any other Directors, supervisors, senior management, substantial or controlling shareholders of the Company; and (iii) she does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As of the date of this announcement, Ms. Liu has confirmed that (i) she meets the independence criteria set out in rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”); (ii) she has no past or present financial or other interests in the business of the Company or its subsidiaries and does not have any connection with any of the Company's core connected persons (as defined in the Listing Rules); and (iii) there are no other factors which might affect her independence.

There is no other information in relation to her appointment that needs to be disclosed pursuant to the requirements of rule 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to the proposed appointment of independent non-executive Director that needs to be brought to the attention of the Shareholders.

Ms. Liu, is entitled to a director's fee of RMB200,000 (before tax) per annum, which is determined in accordance with the Company's remuneration policy and with reference to the level of remuneration paid by comparable companies, the time commitment of the Director, duties and responsibilities in the Group, her qualification and experience. She is entitled to travel expenses to attend relevant meetings and events of the Company and expenses incurred in the exercise of her duties in accordance with the articles of association of the Company. The Company will also disclose the total remuneration received by the Director in the annual report accordingly. After the appointment of Ms. Liu comes into effect, the Company will enter into a service contract with her.

The nomination committee of the Company and the Board, upon receipt of the proposal for the appointment of Ms. Liu as an independent non-executive Director and her profile, have considered various factors relating to the diversity of the Board's membership, including but not limited to gender, age, cultural and educational backgrounds, professional experience, skills, knowledge and industry and geographical experience, in determining the suitability of Ms. Liu to serve as an independent non-executive Director.

The Board is of the view that (i) Ms. Liu has an excellent professional background and extensive working experience; and (ii) based on the assessment conducted, Ms. Liu meets the independence requirements as set out in rule 3.13 of the Listing Rules, and will inject new impetus into the subsequent management and development of the Company after Ms. Liu joins the Company as an independent non-executive Director. Accordingly, the Board has proposed a resolution to the Shareholders to consider the appointment of Ms. Liu as an independent non-executive Director. The Board has also taken into account that Ms. Liu does not hold any directorship in other listed companies and is capable of devoting sufficient time and effort to perform her duties as an independent non-executive Director. In view of the above, the Board considers that Ms. Liu will be able to make valuable contribution to the Company.

## **Circular**

A circular containing, among other things, further details of the proposed appointment of independent non-executive Director, together with the notice of the EGM, will be dispatched to the Shareholders in due course.

By Order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, February 27, 2024

*As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Dr. Yang Bo, Mr. Liu Kai Yu Kenneth and Mr. Yuan Huagang.*

\* *For identification purpose only*